Peripheral Neuropathy Trial, Recruiting NCT07248631 Sponsor: Riphah International University Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT07248631
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with diabetic polyneuropathy (nerve damage related to diabetes), confirmed by their medical history and a clinical examination.
  • People who experience pain and disability in their foot or ankle, with a pain level of 4 or more on a standard 0–10 pain rating scale.
  • People who are able to walk at least 10 metres independently, without assistance.
  • People aged between 40 and 75 years.
  • People who are able to understand and follow exercise instructions.
  • People who have had at most one toe amputated, and not the big toe.
  • People who are willing to take part in the study and sign a consent form.

Who may not be able to join:

  • People who currently have an open wound (ulcer) on the sole of their foot, or gangrene.
  • People who have had surgery on their knee, ankle, or hip in the past, or who are expected to need such surgery during the study period.
  • People who have an artificial joint (such as a knee or hip replacement) in their lower limbs, or who are expected to need one during the study period, or who use a rigid brace or orthosis on their lower limbs.
  • People who are currently participating in another exercise program or research study.
  • People who have dementia or are unable to provide consistent and reliable information.
  • People who have been diagnosed with a neurological disease (a condition affecting the nervous system) other than diabetic neuropathy.
  • People whose nerve pain is caused by something other than diabetes, such as HIV or chemotherapy.
  • People who have serious blood vessel complications or severe damage to the blood vessels of the eyes (severe retinopathy).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Fatima Tariq, MS, Riphah International University

Phone: 923344255033

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
17 October 2024
Est. completion
30 November 2025

Where this trial is recruiting

🇵🇰 Pakistan

Primary endpoints

Numeric Pain Rating Scale

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov